Homepage Top Section2

The approval is for the use of the KEYTRUDA dosage in both monotherapy and combination therapy. According to Merck, the FDA granted the accelerated approval of the new

The company’s AAVSmartLibrary and associated technology are said to be used for developing AAV capsids for enhanced tissue tropism, manufacturability, and pre-existing immunity. The collaboration will make use

Lynparza delivered the result in the PROfound trial, which is being carried out in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene

The randomised and global phase III study will evaluate the efficacy of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious

Systemic sclerosis (SSc), also called as scleroderma, is a disfiguring, disabling and fatal rare autoimmune disease. Nintedanib is a tyrosine kinase inhibitor designed to target crucial receptors engaged

The trial dubbed CheckMate -743 saw the Opdivo, Yervoy combination delivered a statistically significant and clinically meaningful improvement in overall survival (OS) compared to chemotherapy comprised of pemetrexed

The Danish pharma company said that the four-week fixed dose, blinded portion of PaTH Forward, which is assessing the safety, tolerability and efficacy of TransCon PTH in the

According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical